Pancreatic Cancer Research

Clinical trialPhase 2Terminated

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer

NCT04698915↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome
Stopped earlyFutility Analysis (Efficacy or futility)
Phase
Phase 2
Status
Terminated
Study type
Interventional
Start
7 May 2021
Expected end
30 November 2023
Enrollment
177 participants
Sites
35
Primary outcomes
Overall Survival
Sponsor
Industry
Results posted
2024-05-21
Last update
21 May 2024

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Overall Survival [From randomization of the first subject until 30 days post last dose of GC4711/ and SBRT for the last subject randomized to the study (total duration 2years and 6.5 months)]. Count Of Participants, Participants. Arm A Active GC4711 (n=84): 24; Arm B Placebo (n=84): 20.

Papers 3